Jul 30, 2024 · Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.

Find the latest Protagonist Therapeutics, Inc. (PTGX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Jan 24, 2025 · PTGX | Complete Protagonist Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Get the latest Protagonist Therapeutics Inc (PTGX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Discover real-time Protagonist Therapeutics, Inc. Common Stock (PTGX) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with...

12 hours ago · PTGX market cap is currently $2.25B and has a P/E ratio of 14.16. Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock.

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Jan 31, 2025 · Should You Buy or Sell Protagonist Therapeutics Stock? Get The Latest PTGX Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat.

View the latest Protagonist Therapeutics Inc. (PTGX) stock price, news, historical charts, analyst ratings and financial information from WSJ.

View Protagonist Therapeutics, Inc. PTGX stock quote prices, financial information, real-time forecasts, and company news from CNN.